Affiliation: Massachusetts General Hospital
- Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screeningPamela M McMahon
Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, Boston, MA 02114, USA
Risk Anal 32:S117-24. 2012..0% (42.0% in men, 33.3% in women). The adoption of annual screening would have prevented less than half as many lung cancer deaths as the elimination of cigarette smoking...
- Chapter 13: CISNET lung models: comparison of model assumptions and model structuresPamela M McMahon
Institute of Technology Assessment, 101 Merrimac St, Boston, MA 02114 4724, USA
Risk Anal 32:S166-78. 2012..This article highlights aspects of the models that are most relevant to similarities of or differences between the results. Structured comparisons can increase the transparency of these complex models...
- Estimation of mortality rates for disease simulation models using Bayesian evidence synthesisPamela M McMahon
Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA 02114, USA
Med Decis Making 26:497-511. 2006..This approach is suggested when modeling a disease that causes a large proportion of all-cause mortality, particularly when mortality from the disease of interest and other-cause mortality are both affected by the same risk factor...
- Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening studyPamela M McMahon
Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA
Radiology 248:278-87. 2008....
- Adopting helical CT screening for lung cancer: potential health consequences during a 15-year periodPamela M McMahon
Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
Cancer 113:3440-9. 2008..This study estimated changes in lung cancer outcomes through 2005, had chest CT screening been introduced in 1990...
- Cost-effectiveness of computed tomography screening for lung cancer in the United StatesPamela M McMahon
Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA
J Thorac Oncol 6:1841-8. 2011..Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level...